REFERENCES
1. Krovi SH, Kuchroo VK. Activation pathways that drive CD4(+) T cells to break tolerance in autoimmune diseases(). Immunol Rev.2022;307(1):161-190.
2. Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest.2015;125(6):2194-2202.
3. Theofilopoulos AN, Kono DH, Baccala R. The multiple pathways to autoimmunity. Nat Immunol. 2017;18(7):716-724.
4. Burnett DL, Reed JH, Christ D, Goodnow CC. Clonal redemption and clonal anergy as mechanisms to balance B cell tolerance and immunity.Immunol Rev. 2019;292(1):61-75.
5. Klein L, Kyewski B, Allen PM, Hogquist KA. Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see).Nat Rev Immunol. 2014;14(6):377-391.
6. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-787.
7. Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605-614.
8. Dema B, Charles N. Autoantibodies in SLE: Specificities, Isotypes and Receptors. Antibodies (Basel). 2016;5(1):2.
9. Ujiie H. What’s new in the pathogeneses and triggering factors of bullous pemphigoid. J Dermatol. 2023;50(2):140-149.
10. Buhre JS, Becker M, Ehlers M. IgG subclass and Fc glycosylation shifts are linked to the transition from pre- to inflammatory autoimmune conditions. Front Immunol. 2022;13:1006939.
11. Ferri DM, Nassar C, Manion KP, et al. Elevated levels of interferon-alpha act directly on B cells to breach multiple tolerance mechanisms promoting autoantibody production. Arthritis Rheumatol. 2023.
12. Suurmond J, Atisha-Fregoso Y, Marasco E, et al. Loss of an IgG plasma cell checkpoint in patients with lupus. J Allergy Clin Immunol. 2019;143(4):1586-1597.
13. Zhang Y, Zhang X, Dai HQ, Hu H, Alt FW. The role of chromatin loop extrusion in antibody diversification. Nat Rev Immunol.2022;22(9):550-566.
14. Colas L, Magnan A, Brouard S. Immunoglobulin E response in health and disease beyond allergic disorders. Allergy.2022;77(6):1700-1718.
15. Charles N. Autoimmunity, IgE and FcepsilonRI-bearing cells.Curr Opin Immunol. 2021;72:43-50.
16. Yang Z, Wu CM, Targ S, Allen CDC. IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells.J Exp Med. 2020;217(5).
17. Kinet JP. The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol. 1999;17:931-972.
18. Blank U, Huang H, Kawakami T. The high affinity IgE receptor: a signaling update. Curr Opin Immunol. 2021;72:51-58.
19. Daeron M. Innate myeloid cells under the control of adaptive immunity: the example of mast cells and basophils. Curr Opin Immunol. 2016;38:101-108.
20. El Ansari YS, Kanagaratham C, Burton OT, et al. Allergen-Specific IgA Antibodies Block IgE-Mediated Activation of Mast Cells and Basophils. Front Immunol. 2022;13:881655.
21. Engeroff P, Vogel M. The role of CD23 in the regulation of allergic responses. Allergy. 2021;76(7):1981-1989.
22. Pellefigues C, Dema B, Lamri Y, et al. Prostaglandin D2 amplifies lupus disease through basophil accumulation in lymphoid organs.Nat Commun. 2018;9(1):725.
23. Henault J, Riggs JM, Karnell JL, et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat Immunol. 2016;17(2):196-203.
24. Miyawaki S, Ritchie RF. Heterogeneity of antinucleolar antibody and IgE antinuclear antibody in patients with systemic rheumatic diseases.J Immunol. 1974;113(4):1346-1352.
25. Permin H, Wiik A. The prevalence of IgE antinuclear antibodies in rheumatoid arthritis and systemic lupus erythematosus. Acta Pathol Microbiol Scand C. 1978;86C(5):245-249.
26. Camussi G, Tetta C, Benveniste J. Detection of basophil sensitization by IgE antibodies to nuclear antigens in connective tissue diseases. Int Arch Allergy Appl Immunol. 1982;69(4):358-362.
27. Charles N, Hardwick D, Daugas E, Illei GG, Rivera J. Basophils and the T helper 2 environment can promote the development of lupus nephritis. Nature medicine. 2010;16(6):701-707.
28. Dema B, Pellefigues C, Hasni S, et al. Autoreactive IgE is prevalent in systemic lupus erythematosus and is associated with increased disease activity and nephritis. PloS one. 2014;9(2):e90424.
29. Ettinger R, Karnell JL, Henault J, et al. Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses.Autoimmunity. 2017;50(1):25-36.
30. Dema B, Charles N, Pellefigues C, et al. Immunoglobulin E plays an immunoregulatory role in lupus. J Exp Med.2014;211(11):2159-2168.
31. Pan Q, Gong L, Xiao H, et al. Basophil Activation-Dependent Autoantibody and Interleukin-17 Production Exacerbate Systemic Lupus Erythematosus. Front Immunol. 2017;8:348.
32. Lamri Y, Charles N. IgE in the Pathogenesis of SLE: From Pathogenic Role to Therapeutic Target. Antibodies (Basel). 2020;9(4).
33. Fujimoto S, Arinobu Y, Miyawaki K, et al. Anti-dsDNA IgE induces IL-4 production from basophils, potentially involved in B-cell differentiation in systemic lupus erythematosus. Rheumatology (Oxford). 2023.
34. Dijkstra D, Meyer-Bahlburg A. Human Basophils Modulate Plasma Cell Differentiation and Maturation. J Immunol. 2017;198(1):229-238.
35. Shipman WD, Chyou S, Ramanathan A, et al. A protective Langerhans cell-keratinocyte axis that is dysfunctional in photosensitivity.Sci Transl Med. 2018;10(454).
36. Blank U, Essig M, Scandiuzzi L, Benhamou M, Kanamaru Y. Mast cells and inflammatory kidney disease. Immunol Rev. 2007;217:79-95.
37. Lin L, Gerth AJ, Peng SL. Susceptibility of mast cell-deficient W/Wv mice to pristane-induced experimental lupus nephritis. Immunol Lett. 2004;91(2-3):93-97.
38. Lamri Y, Vibhushan S, Pacreau E, et al. Basophils and IgE contribute to mixed connective tissue disease development. J Allergy Clin Immunol. 2021;147(4):1478-1489 e1411.
39. Loucks A, Maerz T, Hankenson K, Moeser A, Colbath A. The multifaceted role of mast cells in joint inflammation and arthritis.Osteoarthritis Cartilage. 2023.
40. Guo J, Rapoport B, McLachlan SM. Thyroid peroxidase autoantibodies of IgE class in thyroid autoimmunity. Clin Immunol Immunopathol.1997;82(2):157-162.
41. Muino JC, Juarez CP, Luna JD, et al. The importance of specific IgG and IgE autoantibodies to retinal S antigen, total serum IgE, and sCD23 levels in autoimmune and infectious uveitis. J Clin Immunol.1999;19(4):215-222.
42. Mikol DD, Ditlow C, Usatin D, et al. Serum IgE reactive against small myelin protein-derived peptides is increased in multiple sclerosis patients. J Neuroimmunol. 2006;180(1-2):40-49.
43. Wei Q, Jiang Y, Xie J, et al. Analysis of antinuclear antibody titers and patterns by using HEp-2 and primate liver tissue substrate indirect immunofluorescence assay in patients with systemic autoimmune rheumatic diseases. J Clin Lab Anal. 2020;34(12):e23546.
44. Atta AM, Santiago MB, Guerra FG, Pereira MM, Sousa Atta ML. Autoimmune response of IgE antibodies to cellular self-antigens in systemic Lupus Erythematosus. Int Arch Allergy Immunol.2010;152(4):401-406.
45. Brito-Zeron P, Acar-Denizli N, Ng WF, et al. How immunological profile drives clinical phenotype of primary Sjogren’s syndrome at diagnosis: analysis of 10,500 patients (Sjogren Big Data Project).Clin Exp Rheumatol. 2018;36 Suppl 112(3):102-112.
46. Danielides S, Dema B, Rivera J, Illei GG. IgE Autoantibodies Against SSA and SSB in Patients with Sjogren’s Syndrome and Healthy Controls.Arthritis & Rheumatism. 2012;64(S10):S930.
47. Abbara S, Seror R, Henry J, et al. Anti-RNP positivity in primary Sjogren’s syndrome is associated with a more active disease and a more frequent muscular and pulmonary involvement. RMD Open.2019;5(2):e001033.
48. Liem SIE, Neppelenbroek S, Fehres CM, et al. Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: Implications for disease pathogenesis. Semin Arthritis Rheum. 2023;58:152136.
49. Daskalova M, Taskov H, Dimitrova E, Baydanoff S. Humoral and cellular immune response to elastin in patients with systemic sclerosis.Autoimmunity. 1997;25(4):233-241.
50. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy.2022;77(3):734-766.
51. Kolkhir P, Gimenez-Arnau AM, Kulthanan K, Peter J, Metz M, Maurer M. Urticaria. Nat Rev Dis Primers. 2022;8(1):61.
52. Asero R, Ferrer M, Kocaturk E, Maurer M. Chronic Spontaneous Urticaria: The Role and Relevance of Autoreactivity, Autoimmunity and Autoallergy. J Allergy Clin Immunol Pract. 2023.
53. Xiang Y-K, Kolkhir P, Scheffel J, et al. Most patients with autoimmune chronic spontaneous urticaria also have autoallergic urticaria, but not vice versa. The Journal of Allergy and Clinical Immunology: In Practice. 2023.
54. Bar-Sela S, Reshef T, Mekori YA. IgE antithyroid microsomal antibodies in a patient with chronic urticaria. J Allergy Clin Immunol. 1999;103(6):1216-1217.
55. Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol. 1989;84(1):66-71.
56. Turktas I, Gokcora N, Demirsoy S, Cakir N, Onal E. The association of chronic urticaria and angioedema with autoimmune thyroiditis.Int J Dermatol. 1997;36(3):187-190.
57. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase–a novel pathomechanism of chronic spontaneous urticaria? PloS one.2011;6(4):e14794.
58. Sanchez J, Sanchez A, Cardona R. Causal Relationship Between Anti-TPO IgE and Chronic Urticaria by In Vitro and In Vivo Tests.Allergy Asthma Immunol Res. 2019;11(1):29-42.
59. Sanchez J, Sanchez A, Munera M, et al. Presence of IgE Autoantibodies Against Eosinophil Peroxidase and Eosinophil Cationic Protein in Severe Chronic Spontaneous Urticaria and Atopic Dermatitis.Allergy Asthma Immunol Res. 2021;13(5):746-761.
60. Concha LB, Chang CC, Szema AM, Dattwyler RJ, Carlson HE. IgE antithyroid antibodies in patients with Hashimoto’s disease and chronic urticaria. Allergy Asthma Proc. 2004;25(5):293-296.
61. Zhang L, Qiu L, Wu J, et al. IgE and IgG Anti-Thyroid Autoantibodies in Chinese Patients With Chronic Spontaneous Urticaria and a Literature Review. Allergy Asthma Immunol Res. 2022;14(1):131-142.
62. Sanchez J, Sanchez A, Cardona R. Clinical Characterization of Patients with Chronic Spontaneous Urticaria according to Anti-TPO IgE Levels. J Immunol Res. 2019;2019:4202145.
63. Çildağ S, Yenisey Ç, Ünübol M, Şentürk T. Comparison of immunoglobulin E anti-thyroid peroxidase antibodies in patients with Hashimoto thyroiditis and chronic spontaneous urticaria. Med Pharm Rep. 2021;94(1):53-57.
64. Tedeschi A, Lorini M, Asero R. Anti-thyroid peroxidase IgE in patients with chronic urticaria. J Allergy Clin Immunol.2001;108(3):467-468.
65. Kadooka Y, Idota T, Gunji H, et al. A method for measuring specific IgE in sera by direct ELISA without interference by IgG competition or IgG autoantibodies to IgE. Int Arch Allergy Immunol.2000;122(4):264-269.
66. Maurer M, Altrichter S, Schmetzer O, Scheffel J, Church MK, Metz M. Immunoglobulin E-Mediated Autoimmunity. Front Immunol.2018;9:689.
67. Hatada Y, Kashiwakura J, Hayama K, et al. Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients.Int Arch Allergy Immunol. 2013;161 Suppl 2:154-158.
68. Asero R, Marzano AV, Ferrucci S, Lorini M, Carbonelli V, Cugno M. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol. 2020;200(3):242-249.
69. Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876-882.
70. Cugno M, Asero R, Ferrucci S, et al. Elevated IgE to tissue factor and thyroglobulin are abated by omalizumab in chronic spontaneous urticaria. Allergy. 2018;73(12):2408-2411.
71. Su H, Kolkhir P, Scheffel J, et al. One in five patients with chronic spontaneous urticaria has IgE to tissue transglutaminase 2.Allergy. 2023.
72. Shin YS, Suh DH, Yang EM, Ye YM, Park HS. Serum Specific IgE to Thyroid Peroxidase Activates Basophils in Aspirin Intolerant Urticaria.J Korean Med Sci. 2015;30(6):705-709.
73. Kaplan A, Lebwohl M, Gimenez-Arnau AM, Hide M, Armstrong AW, Maurer M. Chronic spontaneous urticaria: Focus on pathophysiology to unlock treatment advances. Allergy. 2023;78(2):389-401.
74. Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases.Clin Exp Allergy. 2021;51(7):915-931.
75. Maurer M, Casale T, Saini S, et al. Dupilumab Significantly Reduces Itch and Hives in Patients With Chronic Spontaneous Urticaria: Results From a Phase 3 Trial (LIBERTY-CSU CUPID Study A). Journal of Allergy and Clinical Immunology. 2022;149(2):AB312.
76. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. Ann Allergy Asthma Immunol.2018;120(2):131-137.
77. Andersen YM, Egeberg A, Gislason GH, Skov L, Thyssen JP. Autoimmune diseases in adults with atopic dermatitis. J Am Acad Dermatol.2017;76(2):274-280 e271.
78. Narla S, Silverberg JI. Association between atopic dermatitis and autoimmune disorders in US adults and children: A cross-sectional study.J Am Acad Dermatol. 2019;80(2):382-389.
79. Hampton SF, Cooke RA. The sensitivity of man to human dander, with particular reference to eczema (allergic dermatitis). Journal of Allergy. 1941;13(1):63-76.
80. Simon FA. On the allergen in human dander. Journal of Allergy. 1944;15(5):338-345.
81. Aichberger KJ, Mittermann I, Reininger R, et al. Hom s 4, an IgE-reactive autoantigen belonging to a new subfamily of calcium-binding proteins, can induce Th cell type 1-mediated autoreactivity. J Immunol. 2005;175(2):1286-1294.
82. Altrichter S, Kriehuber E, Moser J, Valenta R, Kopp T, Stingl G. Serum IgE autoantibodies target keratinocytes in patients with atopic dermatitis. J Invest Dermatol. 2008;128(9):2232-2239.
83. Hide M, Tanaka T, Yamamura Y, Koro O, Yamamoto S. IgE-mediated hypersensitivity against human sweat antigen in patients with atopic dermatitis. Acta Derm Venereol. 2002;82(5):335-340.
84. Kortekangas-Savolainen O, Peltonen S, Pummi K, Kalimo K, Savolainen J. IgE-binding components of cultured human keratinocytes in atopic eczema/dermatitis syndrome and their crossreactivity with Malassezia furfur. Allergy. 2004;59(2):168-173.
85. Mittermann I, Reininger R, Zimmermann M, et al. The IgE-reactive autoantigen Hom s 2 induces damage of respiratory epithelial cells and keratinocytes via induction of IFN-gamma. J Invest Dermatol.2008;128(6):1451-1459.
86. Mothes N, Niggemann B, Jenneck C, et al. The cradle of IgE autoreactivity in atopic eczema lies in early infancy. J Allergy Clin Immunol. 2005;116(3):706-709.
87. Natter S, Seiberler S, Hufnagl P, et al. Isolation of cDNA clones coding for IgE autoantigens with serum IgE from atopic dermatitis patients. FASEB J. 1998;12(14):1559-1569.
88. Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211-1220.
89. Schmid-Grendelmeier P, Fluckiger S, Disch R, et al. IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis. J Allergy Clin Immunol. 2005;115(5):1068-1075.
90. Tanaka A, Tanaka T, Suzuki H, Ishii K, Kameyoshi Y, Hide M. Semi-purification of the immunoglobulin E-sweat antigen acting on mast cells and basophils in atopic dermatitis. Exp Dermatol.2006;15(4):283-290.
91. Valenta R, Duchene M, Pettenburger K, et al. Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science. 1991;253(5019):557-560.
92. Valenta R, Maurer D, Steiner R, et al. Immunoglobulin E response to human proteins in atopic patients. J Invest Dermatol.1996;107(2):203-208.
93. Valenta R, Natter S, Seiberler S, et al. Molecular characterization of an autoallergen, Hom s 1, identified by serum IgE from atopic dermatitis patients. J Invest Dermatol. 1998;111(6):1178-1183.
94. Watanabe K, Muro Y, Sugiura K, Tomita Y. IgE and IgG(4) autoantibodies against DFS70/LEDGF in atopic dermatitis.Autoimmunity. 2011;44(6):511-519.
95. Zeller S, Rhyner C, Meyer N, Schmid-Grendelmeier P, Akdis CA, Crameri R. Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. J Allergy Clin Immunol.2009;124(2):278-285, 285 e271-277.
96. Navarrete-Dechent C, Perez-Mateluna G, Silva-Valenzuela S, Vera-Kellet C, Borzutzky A. Humoral and Cellular Autoreactivity to Epidermal Proteins in Atopic Dermatitis. Arch Immunol Ther Exp (Warsz). 2016;64(6):435-442.
97. Tang TS, Bieber T, Williams HC. Does ”autoreactivity” play a role in atopic dermatitis? J Allergy Clin Immunol. 2012;129(5):1209-1215 e1202.
98. Holmes J, Fairclough LC, Todd I. Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity. Arch Dermatol Res. 2019;311(3):141-162.
99. Seiberler S, Bugajska-Schretter A, Hufnagl P, et al. Characterization of IgE-reactive autoantigens in atopic dermatitis. 1. Subcellular distribution and tissue-specific expression. Int Arch Allergy Immunol. 1999;120(2):108-116.
100. Valenta R, Seiberler S, Natter S, et al. Autoallergy: a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol.2000;105(3):432-437.
101. Schuler CFt, Billi AC, Maverakis E, Tsoi LC, Gudjonsson JE. Novel insights into atopic dermatitis. J Allergy Clin Immunol. 2022.
102. Pellefigues C. IgE Autoreactivity in Atopic Dermatitis: Paving the Road for Autoimmune Diseases? Antibodies (Basel). 2020;9(3).
103. Badloe FMS, De Vriese S, Coolens K, et al. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020;10:34.
104. Balaji H, Heratizadeh A, Wichmann K, et al. Malassezia sympodialis thioredoxin-specific T cells are highly cross-reactive to human thioredoxin in atopic dermatitis. J Allergy Clin Immunol.2011;128(1):92-99 e94.
105. Roesner LM, Swiontek K, Lentz D, et al. Patients With Atopic Dermatitis Sensitized to Pet Dander Mount IgE and T-Cell Responses to Mammalian Cystatins, Including the Human Self-Protein. J Investig Allergol Clin Immunol. 2022;32(5):383-392.
106. Sun J, Gu Y, Li K, Zhang JZ. Co-existence of specific IgE antibodies and T cells reactive to house dust mites and human transglutaminase3/tropomysin in patients with atopic dermatitis.Eur J Dermatol. 2021;31(2):155-160.
107. De Bruyn Carlier T, Badloe FMS, Ring J, Gutermuth J, Kortekaas Krohn I. Autoreactive T cells and their role in atopic dermatitis.J Autoimmun. 2021;120:102634.
108. Roesner LM, Heratizadeh A, Wieschowski S, et al. alpha-NAC-Specific Autoreactive CD8+ T Cells in Atopic Dermatitis Are of an Effector Memory Type and Secrete IL-4 and IFN-gamma. J Immunol.2016;196(8):3245-3252.
109. Cipriani F, Ricci G, Leoni MC, et al. Autoimmunity in atopic dermatitis: biomarker or simply epiphenomenon? J Dermatol.2014;41(7):569-576.
110. Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study.J Dtsch Dermatol Ges. 2010;8(12):990-998.
111. Radi G, Campanti A, Diotallevi F, Martina E, Marani A, Offidani A. A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside. Biomedicines. 2022;10(11).
112. Provost TT, Tomasi TB, Jr. Immunopathology of bullous pemphigoid. Basement membrane deposition of IgE, alternate pathway components and fibrin. Clin Exp Immunol. 1974;18(2):193-200.
113. Messingham KN, Crowe TP, Fairley JA. The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid. Front Immunol. 2019;10:2331.
114. Delaporte E, Dubost-Brama A, Ghohestani R, et al. IgE autoantibodies directed against the major bullous pemphigoid antigen in patients with a severe form of pemphigoid. J Immunol.1996;157(8):3642-3647.
115. Ghohestani RF, Cozzani E, Delaporte E, Nicolas JF, Parodi A, Claudy A. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol. 1998;18(3):202-209.
116. Baba T, Sonozaki H, Seki K, Uchiyama M, Ikesawa Y, Toriisu M. An eosinophil chemotactic factor present in blister fluids of bullous pemphigoid patients. J Immunol. 1976;116(1):112-116.
117. Nieboer C, van Leeuwen HJ. IgE in the serum and on mast cells in bullous pemphigoid. Arch Dermatol. 1980;116(5):555-556.
118. Dopp R, Schmidt E, Chimanovitch I, Leverkus M, Brocker EB, Zillikens D. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol.2000;42(4):577-583.
119. Dimson OG, Giudice GJ, Fu CL, et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol.2003;120(5):784-788.
120. Fairley JA, Fu CL, Giudice GJ. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid.J Invest Dermatol. 2005;125(3):467-472.
121. Ishiura N, Fujimoto M, Watanabe R, et al. Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci. 2008;49(2):153-161.
122. Iwata Y, Komura K, Kodera M, et al. Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid. Arch Dermatol.2008;144(1):41-48.
123. Dresow SK, Sitaru C, Recke A, Oostingh GJ, Zillikens D, Gibbs BF. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol. 2009;160(2):429-432.
124. Messingham KA, Noe MH, Chapman MA, Giudice GJ, Fairley JA. A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid. J Immunol Methods. 2009;346(1-2):18-25.
125. Messingham KN, Srikantha R, DeGueme AM, Fairley JA. FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. J Immunol. 2011;187(1):553-560.
126. Pomponi D, Di Zenzo G, Zennaro D, et al. Detection of IgG and IgE reactivity to BP180 using the ISAC(R) microarray system. Br J Dermatol. 2013;168(6):1205-1214.
127. Messingham KN, Holahan HM, Frydman AS, Fullenkamp C, Srikantha R, Fairley JA. Human eosinophils express the high affinity IgE receptor, FcepsilonRI, in bullous pemphigoid. PloS one. 2014;9(9):e107725.
128. Bing L, Xiping Z, Li L, et al. Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid. Arch Dermatol Res. 2015;307(9):849-854.
129. Ma L, Wang M, Wang X, Chen X, Zhu X. Circulating IgE anti-BP180 autoantibody and its correlation to clinical and laboratorial aspects in bullous pemphigoid patients. J Dermatol Sci. 2015;78(1):76-77.
130. Moriuchi R, Nishie W, Ujiie H, Natsuga K, Shimizu H. In vivo analysis of IgE autoantibodies in bullous pemphigoid: a study of 100 cases. J Dermatol Sci. 2015;78(1):21-25.
131. Cho YT, Liao SL, Wang LF, Chu CY. High serum anti-BP180 IgE levels correlate to prominent urticarial lesions in patients with bullous pemphigoid. J Dermatol Sci. 2016;83(1):78-80.
132. Kalowska M, Ciepiela O, Kowalewski C, Demkow U, Schwartz RA, Wozniak K. Enzyme-linked Immunoassay Index for Anti-NC16a IgG and IgE Auto-antibodies Correlates with Severity and Activity of Bullous Pemphigoid. Acta Derm Venereol. 2016;96(2):191-196.
133. Hashimoto T, Ohzono A, Teye K, et al. Detection of IgE autoantibodies to BP180 and BP230 and their relationship to clinical features in bullous pemphigoid. Br J Dermatol.2017;177(1):141-151.
134. van Beek N, Luttmann N, Huebner F, et al. Correlation of Serum Levels of IgE Autoantibodies Against BP180 With Bullous Pemphigoid Disease Activity. JAMA Dermatol. 2017;153(1):30-38.
135. Kamata A, Kurihara Y, Funakoshi T, et al. Basement membrane zone IgE deposition is associated with bullous pemphigoid disease severity and treatment results. Br J Dermatol. 2020;182(5):1221-1227.
136. Saniklidou AH, Tighe PJ, Fairclough LC, Todd I. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res.2018;310(1):11-28.
137. Gasser P, Eggel A. Targeting IgE in allergic disease. Curr Opin Immunol. 2018;54:86-92.
138. Guntern P, Eggel A. Past, present, and future of anti-IgE biologics. Allergy. 2020;75(10):2491-2502.
139. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med. 2011;364(11):1005-1015.
140. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638-649.
141. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151(5):2623-2632.
142. Wright JD, Chu HM, Huang CH, Ma C, Chang TW, Lim C. Structural and Physical Basis for Anti-IgE Therapy. Sci Rep. 2015;5:11581.
143. Davies AM, Allan EG, Keeble AH, et al. Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumab. J Biol Chem. 2017;292(24):9975-9987.
144. Pennington LF, Tarchevskaya S, Brigger D, et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat Commun. 2016;7:11610.
145. Chang TW, Davis FM, Sun NC, Sun CR, MacGlashan DW, Jr., Hamilton RG. Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases.Biotechnology (N Y). 1990;8(2):122-126.
146. Maurer M, Saini SS, McLendon K, et al. Pharmacokinetic equivalence of CT-P39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial. Clin Transl Allergy.2022;12(11):e12204.
147. Zhou B, Lin B, Li J, et al. Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects. MAbs.2012;4(1):110-119.
148. Apsangikar P, Ghadge P, Naik M, Nair S. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma. J Assoc Physicians India. 2020;68(12):61-65.
149. Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020;11(1):165.
150. Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy. 2014;44(11):1371-1385.
151. Kuo BS, Li CH, Chen JB, et al. IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms. J Clin Invest.2022;132(15).
152. Agache I, Rocha C, Pereira A, et al. Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. Allergy.2021;76(1):59-70.
153. Kolkhir P, Munoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria. J Allergy Clin Immunol. 2022;149(6):1819-1831.
154. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109.
155. Gericke J, Metz M, Ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria.J Allergy Clin Immunol. 2017;139(3):1059-1061 e1051.
156. Segu-Verges C, Gomez J, Terradas-Montana P, et al. Unveiling chronic spontaneous urticaria pathophysiology through systems biology.J Allergy Clin Immunol. 2022.
157. Maurer M, Gimenez-Arnau AM, Sussman G, et al. Ligelizumab for Chronic Spontaneous Urticaria. N Engl J Med.2019;381(14):1321-1332.
158. Maurer M, Gimenez-Arnau A, Bernstein JA, et al. Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study. Allergy.2022;77(7):2175-2184.
159. Harris JM, Cabanski CR, Scheerens H, et al. A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria.J Allergy Clin Immunol. 2016;138(6):1730-1732.
160. Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J. 2021;14(3):100519.
161. Chan S, Cornelius V, Cro S, Harper JI, Lack G. Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial. JAMA Pediatr. 2020;174(1):29-37.
162. Iyengar SR, Hoyte EG, Loza A, et al. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol. 2013;162(1):89-93.
163. Bangert CLJ, J.; Weiss, D.; Bieber, T.; Stingl, G. 2(nd) Inflammatory Skin Disease Summit, November 16-19, 2016, New York - Abstract P093. Exp Dermatol. 2016;25 Suppl 4:3-51.
164. Chan SMH, Cro S, Cornelius V, Jahan R, Radulovic S, Lack G. Omalizumab for severe atopic dermatitis in 4- to 19-year-olds: the ADAPT RCT. In: Research SUNIfHaC, ed. Efficacy and Mechanism Evaluation. . Vol 9. Southampton (UK)2022.
165. Hotze M, Baurecht H, Rodriguez E, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy.2014;69(1):132-135.
166. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study.Allergy Asthma Proc. 2008;29(5):530-537.
167. Velling P, Skowasch D, Pabst S, Jansen E, Tuleta I, Grohe C. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy.Eur J Med Res. 2011;16(9):407-410.
168. D’Aguanno K, Gabrielli S, Ouchene L, et al. Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety. J Cutan Med Surg. 2022;26(4):404-413.
169. Castel M, Alexandre M, Jelti L, et al. Updated French guidelines for the therapeutic management of bullous pemphigoid. Ann Dermatol Venereol. 2022;149(2):81-91.
170. Hasni S, Gupta S, Davis M, et al. Safety and Tolerability of Omalizumab: A Randomized Clinical Trial of Humanized Anti-IgE Monoclonal Antibody in Systemic Lupus Erythematosus. Arthritis Rheumatol.2019;71(7):1135-1140.
171. Benito-Villalvilla C, de la Rocha-Munoz A, Lopez-Abente J, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-alpha production and FOXP3(+) Treg generation. Allergy. 2022.
172. Lopez-Abente J, Benito-Villalvilla C, Jaumont X, Pfister P, Tassinari P, Palomares O. Omalizumab restores the ability of human plasmacytoid dendritic cells to induce Foxp3(+)Tregs. Eur Respir J. 2021;57(1).
173. Tsai CT, Mukai K, Robinson PV, et al. Isotype-specific agglutination-PCR (ISAP): A sensitive and multiplex method for measuring allergen-specific IgE. J Allergy Clin Immunol.2018;141(5):1901-1904 e1915.
174. Goyard S, Balbino B, Chinthrajah RS, et al. A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples. Allergy. 2020;75(11):2952-2956.
175. Badloe FMS, De Vriese S, De Bruyn Carlier T, et al. A Novel Method for Total IgE Purification from Human Serum. J Immunol.2022;208(10):2436-2442.
176. Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice. Allergy. 2021;76(8):2420-2432.
177. Santos AF, Kulis MD, Sampson HA. Bringing the Next Generation of Food Allergy Diagnostics Into the Clinic. J Allergy Clin Immunol Pract. 2022;10(1):1-9.
178. Zbaren N, Brigger D, Bachmann D, et al. A novel functional mast cell assay for the detection of allergies. J Allergy Clin Immunol. 2022;149(3):1018-1030 e1011.
179. Luo Y, Fernandez Vallone V, He J, et al. A novel approach for studying mast cell-driven disorders: Mast cells derived from induced pluripotent stem cells. J Allergy Clin Immunol.2022;149(3):1060-1068 e1064.
180. Croote D, Darmanis S, Nadeau KC, Quake SR. High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes. Science. 2018;362(6420):1306-1309.
181. Cao P, Xu W, Zhang L. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.Front Immunol. 2022;13:928621.
182. Kwon IJ, Kim T, Yoo DS, Min S, Kim SC, Kim JH. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid. J Dermatol. 2022.